Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? (Q35154540)

6 August 2017

1 reference

title

Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? (English)

1 reference

6 August 2017

Michael A Weber

1

1 reference

6 August 2017

language of work or name

1 reference

1 June 2003

1 reference

Journal of the Renin-Angiotensin-Aldosterone System

6 August 2017

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

62-73

1 reference

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Telmisartan: a review of its use in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Olmesartan medoxomil: the seventh angiotensin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Study on COgnition and Prognosis in the Elderly (SCOPE).

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Angiotensin II subtype 1 receptor blockers and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Angiotensin receptor blockers: evidence for preserving target organs.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Appropriate Blood Pressure Control in NIDDM (ABCD) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

The Effects of Blood Pressure Reduction in Older Patients: An Overview of Five Randomized Controlled Trials in Elderly Hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.3317%2FJRAAS.2003.015

21 January 2018

Identifiers

DOI

10.3317/JRAAS.2003.015

1 reference

6 August 2017

1 reference